Stem cell transplant plus chemo may be feasible in RCC
San Francisco-Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma appears feasible in a very select, younger, healthier patient population with slow-growing tumors and human leukocyte antigen (HLA)-matched siblings, said Brian I. Rini, MD. He reported results from a University of Chicago Hospital phase II trial at the 37th annual meeting of the American Society of Clinical Oncology here.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.